Abstract
There are various treatment options for hidradenitis suppurativa (HS), a recurrent and suppurative disease, but none is wholly satisfactory or effective. There have been many reports on the efficacy of biologic drugs for the treatment of HS; this article is an in-depth review of the published evidence on this topic. Because the current evidence is limited, randomized, double-blinded, placebo-controlled trials are needed to better elucidate the future of these drugs for the treatment of HS.
Copyright 2010 Elsevier Inc. All rights reserved.
MeSH terms
-
Adalimumab
-
Adolescent
-
Adult
-
Alefacept
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Clinical Trials as Topic
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / therapeutic use*
-
Etanercept
-
Female
-
Hidradenitis Suppurativa / drug therapy*
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use*
-
Infliximab
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / therapeutic use*
-
Therapies, Investigational*
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Dermatologic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins
-
Infliximab
-
Alefacept
-
Adalimumab
-
Etanercept
-
efalizumab